Skip to main content
VTGN
NASDAQ Life Sciences

Vistagen 10-Q: $20.0M Cash, Going Concern Doubt, Nasdaq Deadline Feb 1, 2027

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.181
Mkt Cap
$8.01M
52W Low
$0.164
52W High
$5.14
52W Position info
10% above low
Off High info
96% below high
Rel. Volume
Market data snapshot near publication time

VTGN is trading near its 52-week low of $0.164 (10% above the low).

Summary

Vistagen's fiscal Q2 2027 10-Q shows a narrowed $10.7 million net loss but only $20.0 million of cash and explicit going-concern doubt, with a February 1, 2027 Nasdaq bid-price deadline and a financing or strategic transaction needed to keep operating.


Key Events · Earnings and Guidance · VTGN

  • Q2 Loss Narrows to $10.7M

    Net loss was $10.7 million for the quarter ended September 30, 2026 versus $19.4 million a year earlier, as R&D expense fell to $6.6 million from $15.9 million after the PALISADE program wound down.

  • Cash Falls to $20.0M, Going Concern Doubt

    Cash and cash equivalents dropped to $10.9 million from $30.8 million at March 31, 2026; total cash, cash equivalents and marketable securities of $20.0 million will not fund operations for at least twelve months from the November 13, 2026 issuance date, and management concluded substantial doubt exists about continuing as a going concern.

  • Nasdaq Bid-Price Deadline February 1, 2027

    The company has until February 1, 2027 to hold a $1.00 closing bid for 10 consecutive business days; with the stock at $0.1805, a reverse stock split is the stated likely remedy, and failure would mean suspension and OTC trading.

  • ATM Drip and Warrant Overhang

    Vistagen sold 2,794,123 shares under the Jefferies ATM for $1.3 million net in the six months and another 595,191 shares for $0.2 million net through November 10, 2026; 11,265,086 T2 warrants at $8.877 remain outstanding after the 9,294,022 T1 warrants expired unexercised in August 2026.


Analysis · VTGN · Life Sciences

The headline numbers were already out this morning, but the full 10-Q is where the survival math lives. Cash, cash equivalents and marketable securities totaled $20.0 million at September 30, 2026, against $26.9 million of cash burned in six months, and management states plainly that substantial doubt exists about funding operations beyond twelve months from the November 13, 2026 issuance date. The company's own risk factors spell out the fallback: further workforce cuts, a strategic transaction, bankruptcy protection, or dissolution — with stockholders potentially losing all or substantially all of their investment. Layered on top is the Nasdaq minimum bid price problem: the stock trades at $0.1805 against a $1.00 requirement, with a compliance deadline of February 1, 2027 and a reverse split as the likely cure. The narrowed $10.7 million quarterly loss and the 31% October reduction in force buying roughly $3.2 million a year are real, but they slow the clock rather than stop it.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, VTGN was trading at $0.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8M. The 52-week trading range was $0.16 to $5.14. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

VTGN - Latest Insights

VTGN
Nov 13, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.1805
Real-time Price: $0.1889 info
Change: +$0.0084 (+5%) info
Market Cap: $8.01M info
VTGN
Nov 09, 2026, 8:34 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.172
Real-time Price: $0.1889 info
Change: +$0.0169 (+10%) info
Market Cap: $8.01M info
VTGN
Oct 30, 2026, 5:24 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.1714
Real-time Price: $0.1889 info
Change: +$0.0175 (+10%) info
Market Cap: $8.01M info
VTGN
Oct 09, 2026, 5:15 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.2461
Real-time Price: $0.1889 info
Change: -$0.0572 (-23%) info
Market Cap: $8.01M info
VTGN
Sep 24, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.373
Real-time Price: $0.1889 info
Change: -$0.1841 (-49%) info
Market Cap: $8.01M info